ERBB2 and serous adenocarcinoma: Conversely, in a phase II trial including 61 patients with HER2-positive serous carcinomas, the addition of trastuzumab (initial dose of 8 mg/kg IV, then 6 mg/kg) to CBDCA (area under the curve (AUC5)) + 175 mg/m2 PTX Q3W improved the median PFS in the whole series (12.6 versus 8.0 months, HR = 0.44; 90% CI = 0.26–0.76), in patients with stage III–IV disease (17.9 versus 9.3 months, HR = 0.40, 90% CI = 0.20–0.80) and in patients with recurrent disease (9.2 versus 6.0 months, HR = 0.14; 90% CI = 0.05–0.54) [73].